Abstract:Purpose: Colon cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy. There has been no consensus for p53 as a prognostic marker in colorectal cancer. This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected colon cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy. Experimental design: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for colon adenocarcinoma between May 2004 and November 2007. Tumor expression of the MMR proteins, MLH1 and MSH2, was detected by immunohistochemistry (IHC) in surgically resected tumor specimens. MSI was analyzed by polymerase chain reaction (PCR) amplification using fluorescent dye-labeled primers specific for microsatellite loci. Tumors with MMR defects were defined as those demonstrating loss of MMR protein expression (MMR-D) and/or microsatellite instability high (MSI-H) genotype. Expression patterns of p53 were determined in a semiquantitative manner by light microscopy. Results: There were 13 (9.6%) patients with stage II, 108 (80%) with stage III, and 14 (10.4%) with stage IV. Fourteen patients with stage IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases. In total, 134 tumor specimens were genotyped, 115 specimens were tested by IHC and 113 cases had both genotyping and IHC results available for analysis. Genotyping results demonstrated that 12 (9.0%) cases were MSI-H and 122 (91.0%) were MSI-L/S. By IHC, 11 (9.6%) patients were MMR-D and 104 (90.4%) were MMR-I. The methods were in agreement in 108 patients (94.7%). We assessed 114 patients for p53 expression by immunostaining. MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with colon cancer (n = 135) receiving adjuvant FOLFOX. According to p53 status, there was also no significant difference for DFS (P = 0.11) and OS (P = 0.94). For patients with genotyping/IHC agreement (n = 108), there was no difference in DFS (P = 0.57) and OS (P = 0.98) between patients with MSI-H/MMR-D and MSI-L/S/MMR-I tumors. Conclusion: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection. Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D.

The Relationship of Microsatellite Instability with BRAF and p53 Mutations and Histopathological Parameters in Colorectal Adenocarcinoma

Comparison of Microsatellite Instability With Clinicopathologic Data in Patients With Colon Adenocarcinoma

Association between microsatellite instability status, clinicopathological features and mitochondrial DNA amplification in patients with colorectal cancer

Comparison of histopathologic and clinical characteristics of microsatellite instability in colorectal adenocarcinomas and its impact on survival

Mutation Profile via Next-Generation Sequencing in Patients with Colorectal Adenocarcinoma and Its Clinicopathological Correlation

The Study of the Relationship Between Microsatellite Instability in Adenoma and Adenoma with Malignant Changes of Large Bowel and Proliferation

Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer

Gene mutation profiling in microsatellite instability colorectal cancer and its association with the efficacy of immunotherapy: A retrospective study

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms

Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.

Association of Microsatellite Instability and Gene Expression Profile in Colorectal Carcinoma and Potential Implications for Therapy

Study on the relationship between microsatellite status and clinicopathological charac-teristics of colorectal cancer patients after surgery

Microsatellite Instability of Sporadic Colorectal Carcinomas and Its Clinicopathological Significance

Microsatellite instability in sporadic colorectal cancer and its relationship with clinicopathological features

The Clinical Significance of Microsatellite Instability in Precision Treatment

The Relationship Between DNA Mismatch Repair Status and Clinicopathologic Characteristics in Colon Cancer

Interaction between Microsatellite Instability (MSI) and Tumor DNA Methylation in the Pathogenesis of Colorectal Carcinoma

Reduced Likelihood of Metastases in Patients with Microsatellite-Unstable Colorectal Cancer

A Prospective Blinded Study of Microsatellite Instability (msi) As A Marker of Overall Survival (os) in the Adjuvant Treatment of Colorectal Cancer (crc) Patients.

Microsatellite instability in sporadic and inherited colon adenocarcinomas from Greek patients: correlation with several clinicopathological characteristics